C4 Therapeutics, Inc. (CCCC) has been beaten down lately with too much selling pressure. While the stock has lost 21.9% over the past four weeks, there is light at the end of the tunnel as it is now ...

The price trend for C4 Therapeutics, Inc. (CCCC) has been bearish lately and the stock has lost 7% over the past week. However, the formation of a hammer chart pattern in its last trading session ...

C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the best biotech penny stocks to buy according to analysts. On December 17, Barclays lowered the firm’s price target on C4 Therapeutics to $5 from $10, ...

As of September 13, 2025, the average one-year price target for C4 Therapeutics is $14.79/share. The forecasts range from a low of $3.03 to a high of $52.50. The average price target represents an ...

MANILA, Philippines — State-owned China Communications Construction Co. Ltd. (CCCC) has again expressed its interest in developing the Sangley Point International Airport (SPIA) project in Cavite ...

The latest price target for C4 Therapeutics (NASDAQ:CCCC) was reported by Barclays on December 17, 2025. The analyst firm set a price target for $5.00 expecting CCCC to rise to within 12 months (a ...

C4 Therapeutics, Inc. (CCCC) has been on a downward spiral lately with significant selling pressure. After declining 26.2% over the past four weeks, the stock looks well positioned for a trend ...

The CCCC has developed a coal derived soil amendment to provide a new, non-thermal and a potentially high-volume use for Wyoming coal. A soil amendment is any material added to the soil to improve its ...

A downtrend has been apparent in C4 Therapeutics, Inc. (CCCC) lately with too much selling pressure. The stock has declined 23.1% over the past four weeks. However, given the fact that it is now in ...